Actuate Therapeutics, Inc. filed a quarterly report on Form 10-Q with the SEC covering the period ended September 30, 2026, disclosing a significant decline in cash and a shift to stockholders' deficit.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $2,101,816 as of September 30, 2026, down from $13,159,423 at December 31, 2025, according to the filing.
  • Stockholders' deficit: Total stockholders' equity was reported as ($808,966) at September 30, 2026, compared to positive $7,924,003 at December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $168,520,734 at September 30, 2026, versus $154,607,701 at December 31, 2025.
  • Total assets: Total assets were $3,218,781 at September 30, 2026, down from $14,035,910 at December 31, 2025.
  • Shares outstanding: As of November 13, 2026, 60,382,824 shares of common stock were outstanding.
  • Company classification: Actuate Therapeutics is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, as indicated on the filing's cover page.

Actuate Therapeutics' Balance Sheet Shows Steep Cash Decline Through September 2026

Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biopharmaceutical company based in Fort Worth, Texas, submitted its quarterly report covering the three- and nine-month periods ended September 30, 2026. According to the filing, the company's cash and cash equivalents fell to $2,101,816 from $13,159,423 at December 31, 2025, reflecting the ongoing use of capital to fund operations, including its clinical programs centered on elraglusib, an oral tablet formulation being studied in advanced cancer patients in a Phase 1/2 clinical trial.

The filing reports that total assets declined to $3,218,781 at September 30, 2026, from $14,035,910 at the prior fiscal year-end. On the liabilities side, total current liabilities were $3,622,756, producing total liabilities of $4,027,747. As a result, total stockholders' equity moved from positive $7,924,003 at December 31, 2025 to a deficit of ($808,966) at September 30, 2026, with the accumulated deficit increasing to $168,520,734 from $154,607,701 over the same span.

The company noted in its forward-looking statements section that its ability to fund current operating plans depends on cash on hand as of the report date and its capacity to raise additional capital as needed. Those statements, as the filing cautions, are subject to risks and uncertainties that could cause actual results to differ materially from those expressed. The filing also identifies risks related to maintaining listing of its common stock on the Nasdaq Stock Market and the progress of its elraglusib clinical development program, among others described in the Risk Factors section.

What Was Disclosed

The Form 10-Q for the quarter ended September 30, 2026 discloses Actuate Therapeutics' condensed consolidated balance sheet showing a material reduction in cash, a shift to a stockholders' deficit position, and an accumulated deficit of $168,520,734. The company is an emerging growth company conducting clinical-stage research on elraglusib for cancer treatment, and the filing notes the company's dependence on raising additional capital to sustain its operating plans.